|
1
|
Negoita S, Feuer EJ, Mariotto A, Cronin
KA, Petkov VI, Hussey SK, Benard V, Henley SJ, Anderson RN, Fedewa
S, et al: Annual Report to the Nation on the Status of Cancer, part
II: Recent changes in prostate cancer trends and disease
characteristics. Cancer. 124:2801–2814. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cronin KA, Lake AJ, Scott S, Sherman RL,
Noone AM, Howlader N, Henley SJ, Anderson RN, Firth AU, Ma J, et
al: Annual Report to the Nation on the Status of Cancer, part I:
National cancer statistics. Cancer. 124:2785–2800. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Akaza H, Onozawa M and Hinotsu S: Prostate
cancer trends in Asia. World J Urol. 35:859–865. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
de Bono JS, Oudard S, Ozguroglu M, Hansen
S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L,
et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic
castration-resistant prostate cancer progressing after docetaxel
treatment: A randomised open-label trial. Lancet. 376:1147–1154.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mita AC, Denis LJ, Rowinsky EK, Debono JS,
Goetz AD, Ochoa L, Forouzesh B, Beeram M, Patnaik A, Molpus K, et
al: Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a
novel taxane, administered as a 1-hour infusion every 3 weeks in
patients with advanced solid tumors. Clin Cancer Res. 15:723–730.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pivot X, Koralewski P, Hidalgo JL, Chan A,
Gonçalves A, Schwartsmann G, Assadourian S and Lotz JP: A
multicenter phase II study of XRP6258 administered as a 1-h i.v.
infusion every 3 weeks in taxane-resistant metastatic breast cancer
patients. Ann Oncol. 19:1547–1552. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pezaro CJ, Omlin AG, Altavilla A, Lorente
D, Ferraldeschi R, Bianchini D, Dearnaley D, Parker C, de Bono JS
and Attard G: Activity of cabazitaxel in castration-resistant
prostate cancer progressing after docetaxel and next-generation
endocrine agents. Eur Urol. 66:459–465. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Al Nakouzi N, Le Moulec S, Albigès L, Wang
C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A,
Gajda D, Massard C, et al: Cabazitaxel remains active in patients
progressing after docetaxel followed by novel androgen receptor
pathway targeted therapies. Eur Urol. 68:228–235. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kosaka T and Oya M: Hemorrhagic cystitis
in a patient without a past history of radiation therapy who was
treated with cabazitaxel for CRPC. Ann Oncol. 26:2355–2356. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Watanabe K, Kosaka T, Hongo H, Tamaki S
and Oya M: Headache caused by brain metastases of
castration-resistant prostate cancer during cabazitaxel therapy.
Keio J Med. 66:65–71. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mukai H, Takahashi S, Nozawa M, Onozawa Y,
Miyazaki J, Ohno K and Suzuki K: TED 11576 investigators: Phase I
dose-escalation and pharmacokinetic study (TED 11576) of
cabazitaxel in Japanese patients with castration-resistant prostate
cancer. Cancer Chemother Pharmacol. 73:703–710. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nozawa M, Mukai H, Takahashi S, Uemura H,
Kosaka T, Onozawa Y, Miyazaki J, Suzuki K, Okihara K, Arai Y, et
al: Japanese phase I study of cabazitaxel in metastatic
castration-resistant prostate cancer. Int J Clin Oncol.
20:1026–1034. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Armstrong AJ, Garrett-Mayer E, Yang Ou YC,
Carducci MA, Tannock I, de Wit R and Eisenberger M:
Prostate-specific antigen and pain surrogacy analysis in metastatic
hormone-refractory prostate cancer. J Clin Oncol. 25:3965–3970.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Armstrong AJ, Garrett-Mayer E, de Wit R,
Tannock I and Eisenberger M: Prediction of survival following
first-line chemotherapy in men with castration-resistant metastatic
prostate cancer. Clin Cancer Res. 16:203–211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bando Y, Hinata N, Terakawa T, Furukawa J,
Harada KI, Nakano Y and Fujisawa M: Activity of cabazitaxel in
patients with metastatic castration-resistant prostate cancer after
treatment with single or dual regimens of novel androgen
receptor-targeting agents. Med Oncol. 34:1632017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Belderbos BPS, de Wit R, Hoop EO,
Nieuweboer A, Hamberg P, van Alphen RJ, Bergman A, van der Meer N,
Bins S, Mathijssen RHJ and van Soest RJ: Prognostic factors in men
with metastatic castration-resistant prostate cancer treated with
cabazitaxel. Oncotarget. 8:106468–106474. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Uemura K, Miyoshi Y, Kawahara T, Ryosuke
J, Yamashita D, Yoneyama S, Yokomizo Y, Kobayashi K, Kishida T, Yao
M and Uemura H: Prognostic value of an automated bone scan index
for men with metastatic castration-resistant prostate cancer
treated with cabazitaxel. BMC Cancer. 18:5012018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Meisel A, von Felten S, Vogt DR, Liewen H,
de Wit R, de Bono J, Sartor O and Stenner-Liewen F: Severe
neutropenia during cabazitaxel treatment is associated with
survival benefit in men with metastatic castration-resistant
prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase
III trial. Eur J Cancer. 56:93–100. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kosaka T, Shinojima T, Morita S and Oya M:
Prognostic significance of grade 3/4 neutropenia in Japanese
prostate cancer patients treated with cabazitaxel. Cancer Sci.
109:1570–1575. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shigeta K, Kosaka T, Kitano S, Yasumizu Y,
Miyazaki Y, Mizuno R, Shinojima T, Kikuchi E, Miyajima A, Tanoguchi
H, et al: High absolute monocyte count predicts poor clinical
outcome in patients with castration-resistant prostate cancer
treated with docetaxel chemotherapy. Ann Surg Oncol. 23:4115–4122.
2016. View Article : Google Scholar : PubMed/NCBI
|
